| Site |
Sponsor |
Study Title |
| Brain |
| RTOG0825 |
RTOG |
Phase III Double-Blind Placebo-Controlled Trial Of Conventional Concurrent Chemoradiation And Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation And Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma |
| Breast |
AVF4349n
VIRGO |
GENENTECH |
An Observational study of Treatment Patterns and Safety Outcomes for Metastatic or Local Recurrent Breast Cancer |
| E5103 |
ECOG |
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer |
| PACCT-1 |
ECOG |
Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial |
| Z1071 |
ACOSOG |
A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis |
N063D
ALTTO |
NCCTG |
ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer |
| GI |
| C80405 |
CALGB |
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum **Cetuximab provided** |
| GU |
| C90601 |
CALGB |
A randomized doubled-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinoma |
| E2804 |
ECOG |
E2804 -The Best Trial: A Randomized Phase II study of VEGF, RAF Kinase, mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, Temsirolimus in Advanced Renal Cell Carcinoma |
| E2805 |
ECOG |
Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma |
| Heme |
| CML Registry |
NOVARTIS |
A Worldwide, Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients (The WORLD CML Registry) in routine practice |
| Lung |
| E4508 |
ECOG |
Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-based Therapy |
| Melanoma |
| E1697 |
ECOG |
Phase III Randomized Study of Four Weeks High Dose IFN-"2b in Stage T3 - T4 or N1 (microscopic) Melanoma |